Company: BFRG
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001641172-25-009946
Chunk: 21

Company: BullFrog AI Holdings, Inc.
Filing Date: 2025-05-13
Form: 10-Q
Item: Item 1
Chunk 21
---

evaluating pre-clinical and clinical trial data generated in translational research and clinical trial settings in order to lead to faster,
less expensive drug approvals.

15

Our
aim is to improve the odds of success in each stage of developing medicine, ranging from early pre-clinical through late-stage clinical
development. Our ultimate objective is to utilize bfLEAP™ to enable the success of ongoing third-party clinical trials or rescue
late-stage failed drugs (i.e., Phase II or Phase III clinical trial failures) for in-house development and divestiture. We will also
consider collaborations for earlier stage drugs.

We
intend to continue to evolve and improve bfLEAP™, either in-house or with development partners like JHU-APL. We plan to leverage
our proprietary AI/ML platform developed over several years at one of the top innovation institutions in the world, which has already
been successfully applied in multiple sectors.

We
operate and have staffed our business using funds from our initial public offering and subsequent financings, have entered into partnerships
and relationships, and completed our first commercial service contract with a leading rare disease non-profit organization for AI/ML
analysis of late-stage clinical data in 2023. We have also acquired the rights to a series of preclinical and early clinical drug assets
from universities, as well as entered into a strategic collaboration with a world-renowned research institution to create a HSV1 viral
therapeutic platform to engineer immunotherapies for a variety of diseases. We have signed exclusive worldwide license agreements with
Johns Hopkins University (“JHU”) for a cancer drug that targets glioblastoma (brain cancer), pancreatic cancer, and others.
We have also signed an exclusive worldwide license from George Washington University for another cancer drug that targets hepatocellular
carcinoma (liver cancer) and other liver diseases. In addition, we signed three-year strategic data and commercialization agreements
with the Lieber Institute for Brain Development (“LIBD”) whom we believe has a repository of the largest collection of postmortem
brains in the world, including molecular, clinical, and other data. The objective of this collaboration with LIBD is for the Company
to analyze these rich data sets using its proprietary AI/ML tools and models and then go to market with the discoveries with the ultimate
goal of securing revenue generating strategic partnership deals with biopharmaceutical companies. We intend to secure the rights to other
proprietary data sets and repeat this strategy. Additionally, we